Radionuclides for Targeted Therapy: Physical Properties

被引:46
作者
Stokke, Caroline [1 ,2 ]
Kvassheim, Monika [1 ,3 ]
Blakkisrud, Johan [1 ]
机构
[1] Oslo Univ Hosp, Dept Phys & Computat Radiol, Div Radiol & Nucl Med, POB 4959 Nydalen, N-0424 Oslo, Norway
[2] Univ Oslo, Dept Phys, Problemveien 7, N-0315 Oslo, Norway
[3] Univ Oslo, Div Clin Med, Problemveien 7, N-0315 Oslo, Norway
来源
MOLECULES | 2022年 / 27卷 / 17期
关键词
radionuclide; targeted therapy; radionuclide therapy; radioactivity; molecular radiotherapy; beta; alpha; auger; RADIOLABELED SOMATOSTATIN ANALOG; RADIATION-THERAPY; GROWTH-FACTOR; ALPHA; DOSIMETRY; RADIOIMMUNOTHERAPY; TUMOR; RADIOTHERAPY; CANCER; PHARMACOKINETICS;
D O I
10.3390/molecules27175429
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A search in PubMed revealed that 72 radionuclides have been considered for molecular or functional targeted radionuclide therapy. As radionuclide therapies increase in number and variations, it is important to understand the role of the radionuclide and the various characteristics that can render it either useful or useless. This review focuses on the physical characteristics of radionuclides that are relevant for radionuclide therapy, such as linear energy transfer, relative biological effectiveness, range, half-life, imaging properties, and radiation protection considerations. All these properties vary considerably between radionuclides and can be optimised for specific targets. Properties that are advantageous for some applications can sometimes be drawbacks for others; for instance, radionuclides that enable easy imaging can introduce more radiation protection concerns than others. Similarly, a long radiation range is beneficial in targets with heterogeneous uptake, but it also increases the radiation dose to tissues surrounding the target, and, hence, a shorter range is likely more beneficial with homogeneous uptake. While one cannot select a collection of characteristics as each radionuclide comes with an unchangeable set, all the 72 radionuclides investigated for therapy-and many more that have not yet been investigated-provide numerous sets to choose between.
引用
收藏
页数:20
相关论文
共 100 条
[1]  
Anonymous, 2019, Annals of the ICRP, V48, P9, DOI 10.1177/0146645319834139
[2]  
[Anonymous], EVALUATED NUCL STRUC
[3]  
[Anonymous], RADAR THE RAD DOSE A
[4]  
[Anonymous], FDA APPROVES PLUVICT
[5]  
[Anonymous], 2004, ANN ICRP
[6]  
Attix FH., 2008, INTRO RADIOLOGICAL P
[7]   Therapy using labelled somatostatin analogues:: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide [J].
Barone, Raffaella ;
Walrand, Stephan ;
Konijnenberg, Mark ;
Valkema, Roelf ;
Kvols, Larry K. ;
Krenning, Eric R. ;
Pauwels, Stanislas ;
Jamar, Francois .
NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (03) :283-290
[8]   Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results [J].
Baum, Richard P. ;
Schuchardt, Christiane ;
Singh, Aviral ;
Chantadisai, Maythinee ;
Robiller, Franz C. ;
Zhang, Jingjing ;
Mueller, Dirk ;
Eismant, Alexander ;
Almaguel, Frankis ;
Zboralski, Dirk ;
Osterkamp, Frank ;
Hoehne, Aileen ;
Reineke, Ulrich ;
Smerling, Christiane ;
Kulkarni, Harshad R. .
JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (03) :415-423
[9]   Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors [J].
Bernhardt, P ;
Benjegård, SA ;
Kölby, L ;
Johanson, V ;
Nilsson, O ;
Ahlman, H ;
Forssell-Aronsson, E .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (02) :514-524
[10]   Re-assessing gallium-67 as a therapeutic radionuclide [J].
bin Othman, Muhamad F. ;
Mitry, Nabil R. ;
Lewington, Valerie J. ;
Blower, Philip J. ;
Terry, Samantha Y. A. .
NUCLEAR MEDICINE AND BIOLOGY, 2017, 46 :12-18